For many Nigerians and other diaspora families living in the UK, keeping up with changes to the NHS and public health system is not always straightforward. From navigating GP appointments to understanding new vaccines, official announcements can feel distant or overly technical. That’s why developments like this latest approval from the UK’s medicines regulator matter, especially for adults looking to stay protected in 2026.
The Medicines and Healthcare products Regulatory Agency has confirmed that it has approved zapomeran, also known by its brand name Kostaive, as a COVID-19 vaccine for adults aged 18 and over. The decision was announced on 2 January 2026 and adds another option to the UK’s vaccination programme as the country continues to manage COVID-19 alongside other seasonal illnesses.
Kostaive is administered as a single booster dose injected into the muscle of the upper arm. Unlike earlier vaccines, it uses self-amplifying messenger RNA technology. This means a smaller amount of genetic material is used to instruct the body’s cells to temporarily produce the spike protein found on the COVID-19 virus. In response, the immune system learns to recognise and fight the virus if it encounters it in the future.
According to the MHRA, patient safety was central to the approval process. Julian Beach, the agency’s Interim Executive Director of Healthcare Quality and Access, said the vaccine provides an additional option for preventing COVID-19 in adults, while stressing that its safety will continue to be closely monitored as it is rolled out more widely.
As with other COVID-19 vaccines already in use, some people may experience side effects after receiving Kostaive. These commonly include soreness at the injection site, tiredness, chills, fever, muscle or joint pain, headaches and dizziness. The regulator notes that most of these reactions are mild and typically resolve within a few days.
Detailed safety information will be made available in the official Patient Information Leaflet and the Summary of Product Characteristics, both of which are expected to be published on the MHRA website within a week of approval. Anyone who believes they may be experiencing a side effect is encouraged to speak with a healthcare professional and report it through the MHRA’s Yellow Card scheme, which plays a key role in monitoring medicine safety across the UK.
The approval of Kostaive was granted through the International Recognition Procedure, using an assessment by the European Medicines Agency as the reference decision. This pathway allows the UK to recognise trusted international regulatory decisions while still applying its own standards for safety and effectiveness.
For diaspora communities, particularly Nigerians living and working in the UK, this announcement is a reminder of the importance of staying informed about changes to health policy and vaccination options. Access to clear information can help families make confident decisions about their health, especially in a system that may already feel complex.
At Chijos News, we continue to break down UK health updates in plain language, connecting policy decisions to the real-life experiences of migrants and diaspora households. As 2026 unfolds, staying informed remains one of the most powerful tools for protecting yourself and your community.
